UK biotech races US giants for longevity breakthrough
The Guardian - 05-Nov-2023British researchers and startups vie to outpace tech billionaires in the fight against ageing
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company devoted to research of restoring human health
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
Visit website: https://unitybiotechnology.com/
Details last updated 04-Feb-2019
British researchers and startups vie to outpace tech billionaires in the fight against ageing
UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required
Corporate shift towards ophthalmology puts senolytics head-to-head against existing treatments
Statistically significant treatment effect for both BCVA and CST was seen at both 12 and 18 weeks
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.
Most approaches have their limitations but good progress is being made on several fronts
Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness
More and more companies making greater and greater progress - 2021 could be an exciting year
Comprehensive review of companies' clinical and financial state of play
A new approach to treat diabetic macular oedema
General feeling that failures are bound to happen - but that their approaches can succeed
Disappointing first result - but lessons learnt and plenty of other strategies available
Research community is littered with interesting, promising foundations for therapies to treat aging
Initial results must be promising to enrol more patients at highest dosage
Very early days but good to have more senolytics in the pipeline
Still a long way to go before expanding life span
This therapy uses a modified FOXO4 to promote apoptosis in senescent cells
All the money in the world to fight ageing and death
R&D phase in SENS repair approach has shown promising results
Billionaires are now pouring millions into longevity research. Upgrading the human immune system...